BC Week In Review | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
BC Extra | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
Items per page:
1 - 2 of 2